Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Need for VWF Concentrate Therapy Appears Low

Publish date:: June 19, 2019

Key clinical point: A small number of patients with von Willebrand disease are likely to require treatment with von Willebrand factor concentrate.

Major finding: Just 18% of patients within the cohort required therapy with von Willebrand factor concentrates over the 15-year study period.

Study details: A retrospective analysis of 174 patients with von Willebrand disease.

Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.

Citation:

Boban A et al. Haemophilia. 2019 May 20. doi: 10.1111/hae.13779.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,